Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy-Reference-Cited by-同舟云学术

Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy

Published:2022-03 Issue: Volume:168 Page:1-7
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Cho Yeona,Kim Yejin,Chamseddine Ibrahim,Lee Won Hee,Kim Hye Ryun,Lee Ik Jae,Hong Min Hee,Cho Byung Chul,Lee Chang Geol,Cho Seungryong,Kim Jin Sung,Yoon Hong In,Grassberger Clemens

Funder

Korea Health Industry Development Institute

National Research Foundation of Korea

Yonsei University College of Medicine

National Institutes of Health

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference42 articles.

1. New targeted treatments for non-small-cell lung cancer - role of nivolumab;Zago;Biologics,2016

2. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy;Reiss;Immunotherapy,2014

3. The evolving role of immune checkpoint inhibitors in cancer treatment;Pennock;Oncologist,2015

4. Immune modulation for cancer therapy;Naidoo;Br J Cancer,2014

5. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?;Remon;BMC Med,2017

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives;Clinical and Translational Radiation Oncology;2024-11

2. Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer;Advances in Radiation Oncology;2024-10

3. Lymphopenia associated with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases;Scientific Reports;2024-09-12

4. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

5. The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer;Translational Lung Cancer Research;2024-06